Stem cell therapies for Parkinson's disease: Are trials just around the corner?

Regenerative Medicine

Volumn 9, Issue 5, 2014, Pages 553-555

  Drouin Ouellet, Janelle ^a   Barker, Roger A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

cell therapy; dopaminergic neurons; embryonic stem cells; induced pluripotent stem cells; Parkinson's disease

Indexed keywords

CELL DIFFERENTIATION; CLINICAL TRIAL (TOPIC); CYTOLOGY; DOPAMINERGIC NERVE CELL; EMBRYONIC STEM CELL; HUMAN; PARKINSON DISEASE; PATHOLOGY; PLURIPOTENT STEM CELL; TRANSPLANTATION;

CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; DOPAMINERGIC NEURONS; EMBRYONIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; PARKINSON DISEASE;

EID: 84908702702     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.14.43     Document Type: Editorial

References (13)

1. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 127, 550-560 (2004).
2. Barker RA, Barrett J, Mason SL, Bjorklund A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol. 12, 84-91 (2013).
3. Jankovic J, Poewe W. Therapies in Parkinson's disease. Curr. Opin. Neurol. 25, 433-447 (2012).
4. Kirkeby A, Grealish S, Wolf DA et al. Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep. 1, 703-714 (2012).
5. Kriks S, Shim JW, Piao J et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480, 547-551 (2011).
6. Falk A, Koch P, Kesavan J et al. Capture of neuroepitheliallike stem cells from pluripotent stem cells provides a versatile system for in vitro production of human neurons. PLoS ONE 7, e29597 (2012).
7. Sundberg M, Bogetofte H, Lawson T et al. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells 31, 1548-1562 (2013).
8. Kefalopoulou Z, Politis M, Piccini P et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol. 71, 83-87 (2014).
9. Politis M, Wu K, Loane C et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci. Transl. Med. 2, 38-46 (2010).
10. Freed CR, Greene PE, Breeze RE et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344, 710-719 (2001).
11. Olanow CW, Goetz CG, Kordower JH et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 54, 403-414 (2003).
12. Kim JH, Auerbach JM, Rodriguez-Gomez JA et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418, 50-56 (2002).
13. TRANSNEURO. www.transneuro.org.uk